SCHEMBL2011863

SCHEMBL2011863

CCOC(=O)COc1cc(O)c(C(=O)CN2Cc3cc(C#N)ccc3C2=O)c(OC)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.39
ALK Q9UM73 1/20 0.38
AOC3 Q16853 2/20 0.37
MAPT P10636 2/20 0.37
ADORA2B P29275 2/20 0.37
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
DRD3 P35462 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
KMT2A Q03164 3/20 0.35
PTPN1 P18031 2/20 0.35
MEN1 O00255 2/20 0.34
POLB P06746 1/20 0.34
ADORA2A P29274 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2012577 0.93 ALK (0.41) L3MBTL1ALKAOC3MAPTADORA2B
SCHEMBL2010169 0.87 L3MBTL1 (0.46) L3MBTL1ALKAOC3MAPTADORA2B
SCHEMBL2013236 0.85 HPGD (0.45) L3MBTL1ALKAOC3MAPTADORA2B
SCHEMBL2011564 0.85 ITGB3 (0.39) AOC3ADORA2BKMT2APTPN1MEN1
SCHEMBL2011573 0.84 ALK (0.44) L3MBTL1ALKAOC3MAPTADORA2B
SCHEMBL2012689 0.84 ALK (0.45) L3MBTL1ALKAOC3MAPTGABRA1
SCHEMBL2009941 0.83 ITGB3 (0.38) AOC3ADORA2BKMT2APTPN1MEN1
SCHEMBL2011086 0.83 ITGB3 (0.38) AOC3ADORA2BKMT2APTPN1MEN1
SCHEMBL2013655 0.83 ALK (0.44) L3MBTL1ALKAOC3MAPTADORA2B
SCHEMBL2012555 0.83 ALK (0.44) L3MBTL1ALKAOC3MAPTADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 L3MBTL1 4640/4885ALK 530/4885AOC3 3283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.